0
Skip to Content
B+ | Fighting Childhood Cancer
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
B+ | Fighting Childhood Cancer
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Folder: ABOUT
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Folder: GET INVOLVED
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Folder: RESEARCH
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Folder: NEED HELP?
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
MONTHLY GIVING
DONATE
Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression
Georgia, South Julia Travagline 8/10/21 Georgia, South Julia Travagline 8/10/21

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Uncovering the Contribution of RNA Binding Proteins to Neuroblastoma Aggression

Emory University – Winship Cancer Institute, Atlanta, GA

Read More
A Novel Approach to Target ACVR1 as a Treatment to Pediatric Cancer
Georgia, South Julia Travagline 8/10/21 Georgia, South Julia Travagline 8/10/21

A Novel Approach to Target ACVR1 as a Treatment to Pediatric Cancer

A Novel Approach to Target ACVR1 as a Treatment to Pediatric Cancer

Georgia Tech Research Corporation, Atlanta, GA

Read More
Overcoming Innate Immune Evasion in Pediatric High Grade Glioma
Colorado, West Julia Travagline 8/10/21 Colorado, West Julia Travagline 8/10/21

Overcoming Innate Immune Evasion in Pediatric High Grade Glioma

Overcoming Innate Immune Evasion in Pediatric High Grade Glioma

University of Colorado Denver, AMC and DC, Aurora, CO

Read More
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
Michigan, Midwest Julia Travagline 8/10/21 Michigan, Midwest Julia Travagline 8/10/21

L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia

L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia

The Regents of the University of Michigan, Ann Arbor, MI

Read More
Targeting RNA Processing Defects of Ewing Sarcoma
Texas, South Julia Travagline 8/10/21 Texas, South Julia Travagline 8/10/21

Targeting RNA Processing Defects of Ewing Sarcoma

Targeting RNA Processing Defects of Ewing Sarcoma

UT Health Science Center at San Antonio, San Antonio, TX

Read More
Developing A Novel Therapeutic Strategy for Rhabdomyosarcoma
Texas, South Julia Travagline 8/10/21 Texas, South Julia Travagline 8/10/21

Developing A Novel Therapeutic Strategy for Rhabdomyosarcoma

Developing A Novel Therapeutic Strategy for Rhabdomyosarcoma

UT Southwestern Medical Center, Dallas, TX

Read More
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Texas, South Julia Travagline 8/10/21 Texas, South Julia Travagline 8/10/21

Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML

Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML

Baylor College of Medicine, Houston, TX

Read More
Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics
California, West Julia Travagline 8/10/21 California, West Julia Travagline 8/10/21

Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics

Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics

Stanford University, Stanford, CA

Read More
Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia
Connecticut, Northeast Julia Travagline 8/10/21 Connecticut, Northeast Julia Travagline 8/10/21

Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia

Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia

Yale University, New Haven, CT

Read More
Disrupting Neuroblastoma Tumor-Initiating Cells
New York, Northeast Julia Travagline 8/9/21 New York, Northeast Julia Travagline 8/9/21

Disrupting Neuroblastoma Tumor-Initiating Cells

Disrupting Neuroblastoma Tumor-Initiating Cells

University of Rochester, Rochester, NY

Read More
Epigenetic Drivers in Rhabdomyosarcoma
Washington, West Julia Travagline 8/9/21 Washington, West Julia Travagline 8/9/21

Epigenetic Drivers in Rhabdomyosarcoma

Epigenetic Drivers in Rhabdomyosarcoma

University of Washington, Seattle, WA

Read More
Targeting MEK and CDK4/6 in DIPG
Illinois, Midwest Julia Travagline 8/9/21 Illinois, Midwest Julia Travagline 8/9/21

Targeting MEK and CDK4/6 in DIPG

Targeting MEK and CDK4/6 in DIPG

Lurie Children’s Hospital, Chicago, IL

Read More
Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma
Texas, South Julia Travagline 8/9/21 Texas, South Julia Travagline 8/9/21

Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma

Targeting Beta-Catenin Mediated Activity in Metastatic Osteosarcoma

Baylor College of Medicine, Houston, TX

Read More
Improving Brain Tumor Targeted Antigen Receptor T Cell Function
California, West Julia Travagline 8/9/21 California, West Julia Travagline 8/9/21

Improving Brain Tumor Targeted Antigen Receptor T Cell Function

Improving Brain Tumor Targeted Antigen Receptor T Cell Function

City of Hope, Duarte, CA

Read More
TARGET Pediatric AML Initiative
Julia Travagline 8/9/21 Julia Travagline 8/9/21

TARGET Pediatric AML Initiative

TARGET Pediatric AML Initiative

Children’s Oncology Group

Read More
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Pennsylvania, Northeast Julia Travagline 8/9/21 Pennsylvania, Northeast Julia Travagline 8/9/21

Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)

Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)

Children’s Hospital of Philadelphia, Philadelphia, PA

Read More
In-Vivo Organogenesis Approach to Elucidate Drivers of Medulloblastoma Development and Identify Therapeutic Targets
California, West Julia Travagline 8/9/21 California, West Julia Travagline 8/9/21

In-Vivo Organogenesis Approach to Elucidate Drivers of Medulloblastoma Development and Identify Therapeutic Targets

In-Vivo Organogenesis Approach to Elucidate Drivers of Medulloblastoma Development and Identify Therapeutic Targets

University of California, San Francisco, CA

Read More
Pediatric ALL CAR T-Cell Therapy
Washington, West Julia Travagline 8/9/21 Washington, West Julia Travagline 8/9/21

Pediatric ALL CAR T-Cell Therapy

Pediatric ALL CAR T-Cell Therapy

Seattle Children’s Hospital, Seattle, WA

Read More
Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma
North Carolina, South Julia Travagline 8/9/21 North Carolina, South Julia Travagline 8/9/21

Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma

Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma

Duke University Medical Center, Durham, NC

Read More
Tumorigenesis of a Pediatric Liver Cancer
New York, Northeast Julia Travagline 8/9/21 New York, Northeast Julia Travagline 8/9/21

Tumorigenesis of a Pediatric Liver Cancer

Tumorigenesis of a Pediatric Liver Cancer

The Rockefeller University, New York, NY

Read More
Newer Posts
Older Posts

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark